FDG-PET comparative effectiveness data sought by AHCPR in ongoing technology review.
Executive Summary
FDG-PET MEDICARE TECHNOLOGY ASSESSMENT: AHCPR SEEKS SCIENTIFIC DATA on use of the imaging modality "as a diagnostic and management tool for use in patients with focal or partial epilepsy," the Agency for Health Care Policy & Research said in an Aug. 14 Federal Register notice. The ongoing evaluation of fluorodeoxyglucose positron emission tomography imaging will form the basis of the Health Care Financing Administration's Medicare coverage decision on the technology.